A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

被引：10

作者：

Conte, Benedetta ^{[1
,2
]}

Braso-Maristany, Fara ^{[1
,2
,3
]}

Hernandez, Adela Rodriguez ^{[1
,2
]}

Pascual, Tomas ^{[1
,2
,4
]}

Villacampa, Guillermo ^{[3
,4
,5
]}

Schettini, Francesco ^{[1
,2
,6
]}

Losada, Maria J. Vidal ^{[1
,2
,4
,6
,7
]}

Segui, Elia ^{[1
,2
,4
]}

Angelats, Laura ^{[1
,2
]}

Garcia-Fructuoso, Isabel ^{[1
,2
]}

Gomez-Bravo, Raquel ^{[1
,2
]}

Lorman-Carbo, Natalia ^{[1
]}

Pare, Laia ^{[3
]}

Marin-Aguilera, Mercedes ^{[3
]}

Martinez-Saez, Olga ^{[1
,2
]}

Adamo, Barbara ^{[1
,2
]}

Sanfeliu, Esther ^{[1
,8
]}

Fratini, Beatrice ^{[1
]}

Falato, Claudette ^{[1
,4
]}

Chic, Nuria ^{[1
,2
]}

Vivancos, Ana ^{[3
,9
]}

Villagrasa, Patricia ^{[3
]}

Staaf, Johan ^{[10
]}

Parker, Joel S. ^{[11
]}

Perou, Charles M. ^{[11
,12
]}

Prat, Aleix ^{[1
,2
,3
,6
,7
]}

机构：

[1] August Pi i Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapies Solid Tumors G, Barcelona, Spain

[2] Hosp Clin Barcelona, Canc Inst & Blood Dis, Barcelona, Spain

[3] Reveal Genom, Barcelona, Spain

[4] SOLTI Cooperat Grp, Barcelona, Spain

[5] Vall dHebron Inst Oncol, Oncol Data Sci, Barcelona, Spain

[6] Univ Barcelona, Dept Med, Barcelona, Spain

[7] Hosp QuironSalud, Inst Oncol IOB, Barcelona, Spain

[8] Hosp Clin Barcelona, Pathol Dept, Barcelona, Spain

[9] Vall dHebron Inst Oncol VHIO, Canc Genom Grp, Barcelona, Spain

[10] Lund Univ, Dept Lab Med, Div Translat Canc Res, Lund, Sweden

[11] Univ N Carolina, Dept Genet, Chapel Hill, NC USA

[12] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

来源：

EBIOMEDICINE | 2024年 / 102卷

关键词：

Triple-negative breast cancer (TNBC); Pathological complete response (pCR); Event-free survival (EFS); Overall survival (OS); B-cell/immunoglobulin signature (IGG); Prognostic biomarkers; Predictive biomarkers; Gene expression; TUMOR-INFILTRATING LYMPHOCYTES; STANDARD NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; RANDOMIZED PHASE-II; PROGNOSTIC VALUE; PREDICTIVE-VALUE; CARBOPLATIN; PACLITAXEL; RISK; DOXORUBICIN;

D O I：

10.1016/j.ebiom.2024.105043

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Early -stage triple -negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools aiding in treatment decisions for TNBC. This study aims to assess the effectiveness of a B -cell/ immunoglobulin signature (IGG) alone, or in combination with tumor burden, in predicting prognosis and treatment response in patients with TNBC. Methods Genomic and clinical data were retrieved from 7 cohorts: SCAN -B (N = 874), BrighTNess (n = 482), CALGB40603 (n = 389), METABRIC (n = 267), TCGA (n = 118), GSE58812 (n = 107), GSE21653 (n = 67). IGG and a risk score integrating IGG with tumor/nodal staging (IGG-Clin) were assessed for event -free survival (EFS) and overall survival (OS) in each cohort. Random effects model was used to derive pooled effect sizes. Association of IGG with pathological complete response (pCR) was assessed in CALGB-40603 and BrighTNess. Immune significance of IGG was estimated through CIBERSORTx and EcoTyper. Findings IGG was associated with improved EFS (pooled HR = 0.77, [95% CI = 0.70-0.85], I2 = 18%) and OS (pooled HR = 0.79, [0.73-0.85], I2 = 0%) across cohorts, and was predictive of pCR in CALGB-40603 (OR 1.25, [1.10-1.50]) and BrighTNess (OR 1.57 [1.25-1.98]). IGG-Clin was predictive of recurrence (pooled HR = 2.11, [1.75-2.55], I2 = 0%) and death (pooled HR = 1.99, 95% [0.84-4.73], I2 = 79%) across cohorts. IGG was associated with adaptive immune response at CIBERSORTx and EcoTyper analysis. Interpretation IGG is linked to improved prognosis and pCR in early -stage TNBC. The integration of IGG alongside tumor and nodal staging holds promise as an approach to identify patients benefitting from intensified or deintensified treatments. Agencia de Gesto d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III, Fundacion Contigo, Asociacion Cancer de Mama Metastasico IV, Breast Cancer Research Foundation, RESCUER, Fundacion cientifica AECC and FSEOM. Copyright (c) 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

引用

页数：15

共 50 条

[11] Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era? [J].

Gupta, Ravi Kumar ;

Roy, Arya Mariam ;

Gupta, Ashish ;

Takabe, Kazuaki ;

Dhakal, Ajay ;

Opyrchal, Mateusz ;

Kalinski, Pawel ;

Gandhi, Shipra .

CANCERS, 2022, 14 (08)

[12] TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy [J].

Martin, M. ;

Stecklein, S. R. ;

Gluz, O. ;

Villacampa, G. ;

Monte-Millan, M. ;

Nitz, U. ;

Cobo, S. ;

Christgen, M. ;

Braso-Maristany, F. ;

Alvarez, E. L. ;

Echavarria, I. ;

Conte, B. ;

Kuemmel, S. ;

Bueno-Muino, C. ;

Jerez, Y. ;

Kates, R. ;

Cebollero, M. ;

Kolberg-Liedtke, C. ;

Bueno, O. ;

Garcia-Saenz, J. a. ;

Moreno, F. ;

Grischke, E. -m. ;

Forstbauer, H. ;

Braun, M. ;

Warm, M. ;

Hackmann, J. ;

Uleer, C. ;

Aktas, B. ;

Schumacher, C. ;

Wuerstleins, R. ;

Graeser, M. ;

zu Eulenburg, C. ;

Kreipe, H. H. ;

Gomez, H. ;

Massarrah, T. ;

Herrero, B. ;

Pare, L. ;

Bohn, U. ;

Lopez-Tarruella, S. ;

Vivanco, A. ;

Sanfeliu, E. ;

Parker, J. S. ;

Perou, C. M. ;

Villagrasa, P. ;

Prat, A. ;

Sharma, P. ;

Harbeck, N. .

ANNALS OF ONCOLOGY, 2025, 36 (02) :158-171

[13] Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab [J].

Bagegni, Nusayba A. ;

Davis, Andrew A. ;

Clifton, Katherine K. ;

Ademuyiwa, Foluso O. .

BREAST CANCER-TARGETS AND THERAPY, 2022, 14 :113-123

[14] Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer [J].

Hao, Xiaopeng ;

Gao, Xianqi ;

Yin, Shanshan ;

Jiang, Zefei .

TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4

[15] Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer [J].

Yu, Zhigang .

TRANSLATIONAL BREAST CANCER RESEARCH, 2024, 5

[16] The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer [J].

Duan, Fangfang ;

Zhong, Muyi ;

Ye, Jinhui ;

Wang, Li ;

Jiang, Chang ;

Yuan, Zhongyu ;

Bi, Xiwen ;

Huang, Jiajia .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10

[17] Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2+Breast Cancer [J].

Phadke, Sneha .

CURRENT ONCOLOGY REPORTS, 2022, 24 (12) :1779-1789

[18] Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis [J].

Ghafouri, Sanaz N. ;

Nayeri, Rebecca W. ;

McAndrew, Nicholas P. ;

Hurvitz, Sara A. .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14

[19] The potential benefits of radiotherapy in elderly patients with early-stage triple-negative breast cancer [J].

Xu, Zheng ;

Qin, Chengdong ;

Cao, Binxiao ;

Ruan, Pengcheng ;

Zhang, Mianhao ;

Chen, Guidong .

FRONTIERS IN MEDICINE, 2025, 11

[20] Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer [J].

Haiderali, Amin ;

Rhodes, Whitney C. ;

Gautam, Santosh ;

Huang, Min ;

Sieluk, Jan ;

Skinner, Karen E. ;

Schwartzberg, Lee S. .

FUTURE ONCOLOGY, 2021, 17 (29) :3833-3841

← 1 2 3 4 5 →